| Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations S Rodríguez-Nóvoa, P Labarga, A D'avolio, P Barreiro, M Albalate, ... Aids 24 (7), 1064-1066, 2010 | 168 | 2010 |
| Validation of a rapid and sensitive high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) assay for the simultaneous determination of existing and new … L Else, V Watson, J Tjia, A Hughes, M Siccardi, S Khoo, D Back Journal of Chromatography B 878 (19), 1455-1465, 2010 | 164 | 2010 |
| HPLC–MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients A D’Avolio, M Siccardi, M Sciandra, B Lorena, S Bonora, L Trentini, ... Journal of Chromatography B 859 (2), 234-240, 2007 | 146 | 2007 |
| New HPLC–MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma S De Francia, A D’Avolio, F De Martino, E Pirro, L Baietto, M Siccardi, ... Journal of Chromatography B 877 (18-19), 1721-1726, 2009 | 136 | 2009 |
| An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 … A D'Avolio, L Baietto, M Siccardi, M Sciandra, M Simiele, V Oddone, ... Therapeutic Drug Monitoring 30 (6), 662-669, 2008 | 132 | 2008 |
| Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing … C Wyen, H Hendra, M Siccardi, M Platten, H Jaeger, T Harrer, S Esser, ... Journal of antimicrobial chemotherapy 66 (9), 2092-2098, 2011 | 130 | 2011 |
| Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling DM Moss, M Siccardi British journal of pharmacology 171 (17), 3963-3979, 2014 | 115 | 2014 |
| Physiologically based pharmacokinetic modelling to inform development of intramuscular long-acting nanoformulations for HIV RKR Rajoli, DJ Back, S Rannard, CL Freel Meyers, C Flexner, A Owen, ... Clinical pharmacokinetics 54, 639-650, 2015 | 111 | 2015 |
| HPLC–MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions A D’Avolio, M Simiele, M Siccardi, L Baietto, M Sciandra, S Bonora, ... Journal of pharmaceutical and biomedical analysis 52 (5), 774-780, 2010 | 110 | 2010 |
| Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro–in vivo correlation TO McDonald, M Giardiello, P Martin, M Siccardi, NJ Liptrott, D Smith, ... Advanced healthcare materials 3 (3), 400-411, 2014 | 95 | 2014 |
| Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma L Baietto, A D’Avolio, FG De Rosa, S Garazzino, M Michelazzo, ... Analytical and bioanalytical chemistry 396, 791-798, 2010 | 93 | 2010 |
| Association of a Single-Nucleotide Polymorphism in the Pregnane X Receptor (PXR 63396C→T) with Reduced Concentrations of Unboosted Atazanavir M Siccardi, A D'Avolio, L Baietto, S Gibbons, M Sciandra, D Colucci, ... Clinical infectious diseases 47 (9), 1222-1225, 2008 | 93 | 2008 |
| Population pharmacokinetic modeling of the association between 63396C→ T pregnane X receptor polymorphism and unboosted atazanavir clearance A Schipani, M Siccardi, A D'Avolio, L Baietto, M Simiele, S Bonora, ... Antimicrobial agents and chemotherapy 54 (12), 5242-5250, 2010 | 91 | 2010 |
| Long-acting drugs and formulations for the treatment and prevention of HIV infection C Flexner, A Owen, M Siccardi, S Swindells International journal of antimicrobial agents 57 (1), 106220, 2021 | 83 | 2021 |
| Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations M Simiele, A D'Avolio, L Baietto, M Siccardi, M Sciandra, S Agati, J Cusato, ... Antimicrobial agents and chemotherapy 55 (6), 2976-2978, 2011 | 80 | 2011 |
| A HPLC–MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium … A D’Avolio, M Simiele, M Siccardi, L Baietto, M Sciandra, V Oddone, ... Journal of pharmaceutical and biomedical analysis 54 (4), 779-788, 2011 | 77 | 2011 |
| Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals A Schipani, C Wyen, T Mahungu, H Hendra, D Egan, M Siccardi, ... Journal of antimicrobial chemotherapy 66 (6), 1332-1339, 2011 | 72 | 2011 |
| Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir DM Moss, WS Kwan, NJ Liptrott, DL Smith, M Siccardi, SH Khoo, DJ Back, ... Antimicrobial agents and chemotherapy 55 (2), 879-887, 2011 | 72 | 2011 |
| Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients A D’Avolio, A Ibañez, M Sciandra, M Siccardi, DG de Requena, S Bonora, ... Journal of Chromatography B 835 (1-2), 127-130, 2006 | 68 | 2006 |
| Repository describing an aging population to inform physiologically based pharmacokinetic models considering anatomical, physiological, and biological age-dependent changes F Stader, M Siccardi, M Battegay, H Kinvig, MA Penny, C Marzolini Clinical pharmacokinetics 58, 483-501, 2019 | 67 | 2019 |
Antonio D'AvolioUniversity of Turin, Medical Sciences Dpt., Lab. Clinical Pharmacology and Pharmacogenetics在 unito.it 的电子邮件经过验证
